MTOR and hereditary hemorrhagic telangiectasia: The use of an mTOR inhibitor-based immunosuppression regimen may be useful for these patients, as sirolimus block the overactivated PI3K signaling pathway in HHT reducing vascular growth and may reduce allograft recurrence [4,5,13,14,71].